Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice

Spinal muscular atrophy (SMA) is a monogenic neuromuscular disease caused by low levels of the Survival Motor Neuron (SMN) protein. Motor neuron degeneration is the central hallmark of the disease. However, the SMN protein is ubiquitously expressed and depletion of the protein in peripheral tissues...

Full description

Bibliographic Details
Main Authors: Lucia Chehade, Marc-Olivier Deguise, Yves De Repentigny, Rebecca Yaworski, Ariane Beauvais, Sabrina Gagnon, Niko Hensel, Rashmi Kothary
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fncel.2022.972029/full
_version_ 1828518289003773952
author Lucia Chehade
Lucia Chehade
Lucia Chehade
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Yves De Repentigny
Rebecca Yaworski
Ariane Beauvais
Sabrina Gagnon
Niko Hensel
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
author_facet Lucia Chehade
Lucia Chehade
Lucia Chehade
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Yves De Repentigny
Rebecca Yaworski
Ariane Beauvais
Sabrina Gagnon
Niko Hensel
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
author_sort Lucia Chehade
collection DOAJ
description Spinal muscular atrophy (SMA) is a monogenic neuromuscular disease caused by low levels of the Survival Motor Neuron (SMN) protein. Motor neuron degeneration is the central hallmark of the disease. However, the SMN protein is ubiquitously expressed and depletion of the protein in peripheral tissues results in intrinsic disease manifestations, including muscle defects, independent of neurodegeneration. The approved SMN-restoring therapies have led to remarkable clinical improvements in SMA patients. Yet, the presence of a significant number of non-responders stresses the need for complementary therapeutic strategies targeting processes which do not rely solely on restoring SMN. Dysregulated cell death pathways are candidates for SMN-independent pathomechanisms in SMA. Receptor-interacting protein kinase 1 (RIPK1) and RIPK3 have been widely recognized as critical therapeutic targets of necroptosis, an important form of programmed cell death. In addition, Caspase-1 plays a fundamental role in inflammation and cell death. In this study, we evaluate the role of necroptosis, particularly RIPK3 and Caspase-1, in the Smn2B/− mouse model of SMA. We have generated a triple mutant (TKO), the Smn2B/−; Ripk3−/−; Casp1−/− mouse. TKO mice displayed a robust increase in survival and improved motor function compared to Smn2B/− mice. While there was no protection against motor neuron loss or neuromuscular junction pathology, larger muscle fibers were observed in TKO mice compared to Smn2B/− mice. Our study shows that necroptosis modulates survival, motor behavior and muscle fiber size independent of SMN levels and independent of neurodegeneration. Thus, small-molecule inhibitors of necroptosis as a combinatorial approach together with SMN-restoring drugs could be a future strategy for the treatment of SMA.
first_indexed 2024-12-11T18:53:10Z
format Article
id doaj.art-7012f123c6254c638026160eccd82345
institution Directory Open Access Journal
issn 1662-5102
language English
last_indexed 2024-12-11T18:53:10Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular Neuroscience
spelling doaj.art-7012f123c6254c638026160eccd823452022-12-22T00:54:14ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022022-08-011610.3389/fncel.2022.972029972029Suppression of the necroptotic cell death pathways improves survival in Smn2B/− miceLucia Chehade0Lucia Chehade1Lucia Chehade2Marc-Olivier Deguise3Marc-Olivier Deguise4Marc-Olivier Deguise5Marc-Olivier Deguise6Yves De Repentigny7Rebecca Yaworski8Ariane Beauvais9Sabrina Gagnon10Niko Hensel11Rashmi Kothary12Rashmi Kothary13Rashmi Kothary14Rashmi Kothary15Rashmi Kothary16Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, CanadaCenter for Neuromuscular Disease, University of Ottawa, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, CanadaCenter for Neuromuscular Disease, University of Ottawa, Ottawa, ON, CanadaDepartment of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, CanadaDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, CanadaCenter for Neuromuscular Disease, University of Ottawa, Ottawa, ON, CanadaDepartment of Medicine, University of Ottawa, Ottawa, ON, CanadaDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, CanadaSpinal muscular atrophy (SMA) is a monogenic neuromuscular disease caused by low levels of the Survival Motor Neuron (SMN) protein. Motor neuron degeneration is the central hallmark of the disease. However, the SMN protein is ubiquitously expressed and depletion of the protein in peripheral tissues results in intrinsic disease manifestations, including muscle defects, independent of neurodegeneration. The approved SMN-restoring therapies have led to remarkable clinical improvements in SMA patients. Yet, the presence of a significant number of non-responders stresses the need for complementary therapeutic strategies targeting processes which do not rely solely on restoring SMN. Dysregulated cell death pathways are candidates for SMN-independent pathomechanisms in SMA. Receptor-interacting protein kinase 1 (RIPK1) and RIPK3 have been widely recognized as critical therapeutic targets of necroptosis, an important form of programmed cell death. In addition, Caspase-1 plays a fundamental role in inflammation and cell death. In this study, we evaluate the role of necroptosis, particularly RIPK3 and Caspase-1, in the Smn2B/− mouse model of SMA. We have generated a triple mutant (TKO), the Smn2B/−; Ripk3−/−; Casp1−/− mouse. TKO mice displayed a robust increase in survival and improved motor function compared to Smn2B/− mice. While there was no protection against motor neuron loss or neuromuscular junction pathology, larger muscle fibers were observed in TKO mice compared to Smn2B/− mice. Our study shows that necroptosis modulates survival, motor behavior and muscle fiber size independent of SMN levels and independent of neurodegeneration. Thus, small-molecule inhibitors of necroptosis as a combinatorial approach together with SMN-restoring drugs could be a future strategy for the treatment of SMA.https://www.frontiersin.org/articles/10.3389/fncel.2022.972029/fullneuroinflammationnecroptosismotor neuron disease (MND)multi-system diseasemouse genetic models
spellingShingle Lucia Chehade
Lucia Chehade
Lucia Chehade
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Marc-Olivier Deguise
Yves De Repentigny
Rebecca Yaworski
Ariane Beauvais
Sabrina Gagnon
Niko Hensel
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Rashmi Kothary
Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
Frontiers in Cellular Neuroscience
neuroinflammation
necroptosis
motor neuron disease (MND)
multi-system disease
mouse genetic models
title Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
title_full Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
title_fullStr Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
title_full_unstemmed Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
title_short Suppression of the necroptotic cell death pathways improves survival in Smn2B/− mice
title_sort suppression of the necroptotic cell death pathways improves survival in smn2b mice
topic neuroinflammation
necroptosis
motor neuron disease (MND)
multi-system disease
mouse genetic models
url https://www.frontiersin.org/articles/10.3389/fncel.2022.972029/full
work_keys_str_mv AT luciachehade suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT luciachehade suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT luciachehade suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT marcolivierdeguise suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT marcolivierdeguise suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT marcolivierdeguise suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT marcolivierdeguise suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT yvesderepentigny suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rebeccayaworski suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT arianebeauvais suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT sabrinagagnon suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT nikohensel suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rashmikothary suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rashmikothary suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rashmikothary suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rashmikothary suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice
AT rashmikothary suppressionofthenecroptoticcelldeathpathwaysimprovessurvivalinsmn2bmice